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New Biotechnology R&D Center
Established at UNH





DURHAM, N.H. -- A new biotechnology research and
development center has been established at the
University of New Hampshire, in partnership with
leading pharmaceutical firms and with sponsorship
from the National Science Foundation (NSF).
The Biomolecular Interaction Technologies Center
(BITC) at UNH recently qualified as an NSF
Industry/University Cooperative Research Center
(I/UCRC), and is one of only seven biotechnology and
health care sites in the United States. The program
promotes collaboration between industry, academia and
the government by providing seed money for initial
development.
The center will bring in approximately $400,000 each
year to support research at the university. NSF funds
$70,000 annually to pay for administrative costs. After
10 years, centers are expected to become independent
of NSF support.
BITC will develop advanced instruments and methods
for characterizing molecular interactions, especially for
large, complex molecules such as proteins and DNA.
The research at UNH will enable pharmaceutical and
biotechnology companies -- including Eli Lilly and
Company, Pharmacia, Abbott Laboratories, ICOS
Corporation and Sunesis Pharmaceuticals -- to develop
new drugs more effectively and rapidly.
In addition, BITC will provide an environment in which
industry researchers can collaborate with UNH students
and center scientists.
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"With the formation of BITC, UNH is now able to offer
students broad exposure to engineering applications in
molecular biology and biochemistry," says Donald
Sundberg, UNH vice president for research and public
service. "Students will have the opportunity to do
cutting-edge research and gain engineering experience
that will prepare them for a career in a number of fields.
This multidisciplinary approach is available to both
undergraduates and graduate students, and is what
makes the program so attractive to the National Science
Foundation."
The center is directed by Thomas Laue, UNH professor
of biochemistry, and is based in the College of Life
Sciences and Agriculture. It is staffed by faculty
researchers and students from UNH and the University
of Utah.
"Some of our instruments are the only ones of their
kind in the world that can satisfactorily answer the
questions companies have in the early stages of drug
development," says Laue, adding that three of the best
machinists in the world work at UNH's Institute for the
Study of Earth, Oceans, and Space. "It would be cost
prohibitive for companies to create their own
instruments. This partnership allows the consortium
members to share the costs of research and
development, and helps transfer the research that is
being done in an academic setting to industry."
Of the new drugs approved by the FDA in 1999, 60
percent were either proteins or molecules that interact
with naturally occurring proteins. The accurate
description of biomolecular interactions, says Laue, is a
central element in understanding disease mechanisms
and is essential for devising safe and effective
pharmaceuticals.
"The characterization of these interactions is important
to the pharmaceutical and biotechnology industries in
the areas of drug discovery, development and
formulation, and quality assurance/quality control," he
says. "In each of these areas questions arise concerning
the number of molecules interacting and the binding
strength of their interactions.
"For drug discovery, determining the binding strength
between a drug and its target is important since higher
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binding strength often correlates with increased drug
potency and specificity. During drug development, the
mode of delivery, body clearance rates, and the
effective and tolerated doses are necessary
information."
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